Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

17 Oct 2023 15:30

RNS Number : 4182Q
GSK PLC
17 October 2023
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.1487

17

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.1487

15

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Elizabeth McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

7

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

32

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

8

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

4

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Harry Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

4

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jesse Goodman

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

4

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$36.9033

26

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2023-10-13

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFDFEWEDSEIS
Date   Source Headline
25th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20255:00 pmRNSBlenrep approved in the EU for multiple myeloma
24th Jul 20257:00 amRNSTransaction in Own Shares
23rd Jul 20255:00 pmRNSUS FDA review extended for Blenrep
23rd Jul 20257:00 amRNSTransaction in Own Shares
22nd Jul 20257:00 amRNSTransaction in Own Shares
21st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20253:30 pmRNSDirector/PDMR Shareholding
18th Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSBlenrep US ODAC outcome
17th Jul 20257:00 amRNSGSK’s Shingrix Fully Liquid FDA approval
17th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20253:30 pmRNSDirector/PDMR Shareholding
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20253:30 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSGSK submits Arexvy for adults 18-49 AIR to FDA
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares
7th Jul 20254:00 pmRNSGSK completes acquisition of efimosfermin for SLD
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20253:00 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSTransaction in Own Shares
30th Jun 20257:00 amRNSTransaction in Own Shares
27th Jun 20257:00 amRNSTransaction in Own Shares
26th Jun 20257:00 amRNSTransaction in Own Shares
25th Jun 20257:00 amRNSTransaction in Own Shares
24th Jun 20253:30 pmRNSDirector/PDMR Shareholding
24th Jun 20253:00 pmRNSDirector Declaration
24th Jun 20257:00 amRNSTransaction in Own Shares
23rd Jun 20255:50 pmRNSReplacement - Director/PDMR Shareholding
23rd Jun 20253:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20258:30 amRNSReplacement RNS: Linerixibat file accepted by EMA
23rd Jun 20258:18 amRNSGSK Submits Arexvy for adults 18+ with EMA
23rd Jun 20257:00 amRNSTransaction in Own Shares
20th Jun 20257:00 amRNSArexvy filed in Japan for 18-49 at increased risk
20th Jun 20257:00 amRNSTransaction in Own Shares
19th Jun 20257:00 amRNSTransaction in Own Shares
18th Jun 20257:00 amRNSTransaction in Own Shares
17th Jun 20257:00 amRNSTransaction in Own Shares
16th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20253:30 pmRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20257:00 amRNSGSK submits Arexvy for adults 18+ with EMA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.